Table 2.
Complications and other characteristics of pseudocirrhosis (n = 86, unless specified).
| Feature | n (%) |
|---|---|
| Radiological findings | |
| Nodular hepatic contour | 84 (97.7) |
| Capsular retraction | 71 (82.6) |
| Caudate lobe enlargement | 58 (67.4) |
| Segmental or lobar volume loss | 53 (61.6) |
| Signs of portal hypertension | 31 (36.0) |
| New splenomegaly (>12 cm) | 13 (15.1) |
| Esophageal and/or gastric varices | 16 (NAφ) |
| Variceal gastrointestinal bleeding | 8 (9.3) |
| High albumin-gradient ascites | 30 (34.9) |
| Signs of hepatocellular failure | 42 (48.8) |
| Direct hyperbilirubinemia | 41 (47.7) |
| Hepatic encephalopathy | 12 (14.0) |
| New coagulopathy | 26 (30.2) |
| Breast cancer response* | |
| Complete response (CR) | 2 (2.3) |
| Partial response (PR) | 13 (15.1) |
| Stable disease (SD) | 24 (27.9) |
| Progressive disease (PD) | 46 (53.5) |
| Not assessed | 1 (1.2) |
| Status of liver metastases* | |
| Enlarging and/or increasing | 33 (38.4) |
| Shrinking and/or decreasing | 25 (29.1) |
| Stable or mixed response | 19 (22.1) |
| Change in breast cancer therapies¶ | |
| Discontinued chemotherapy | 21/73 (28.8) |
| Discontinued endocrine therapy | 13/42 (30.9) |
| Transitioned to hospice | 17/86 (19.8) |
φ denominator unknown; * at the time of diagnosis of pseudocirrhosis; ¶ within 4 weeks of diagnosis of pseudocirrhosis.